

Stem Cell Biology and Regenerative Medicine

Series Editor

Kursad Turksen, Ph.D.

kturksen@ohri.ca

For further volumes:

<http://www.springer.com/series/7896>

Jaap Jan Boelens • Robert Wynn
Editors

Stem Cell Therapy in Lysosomal Storage Diseases

 Humana Press

Editors

Jaap Jan Boelens
Wilhelmina Childrens Hospital
University Medical Center Utrecht
Utrecht, The Netherlands

Robert Wynn
Royal Manchester Children's Hospital
Manchester, UK

ISSN 2196-8985

ISSN 2196-8993 (electronic)

ISBN 978-1-4614-8356-4

ISBN 978-1-4614-8357-1 (eBook)

DOI 10.1007/978-1-4614-8357-1

Springer New York Heidelberg Dordrecht London

Library of Congress Control Number: 2013949150

© Springer Science+Business Media New York 2013

This work is subject to copyright. All rights are reserved by the Publisher, whether the whole or part of the material is concerned, specifically the rights of translation, reprinting, reuse of illustrations, recitation, broadcasting, reproduction on microfilms or in any other physical way, and transmission or information storage and retrieval, electronic adaptation, computer software, or by similar or dissimilar methodology now known or hereafter developed. Exempted from this legal reservation are brief excerpts in connection with reviews or scholarly analysis or material supplied specifically for the purpose of being entered and executed on a computer system, for exclusive use by the purchaser of the work. Duplication of this publication or parts thereof is permitted only under the provisions of the Copyright Law of the Publisher's location, in its current version, and permission for use must always be obtained from Springer. Permissions for use may be obtained through RightsLink at the Copyright Clearance Center. Violations are liable to prosecution under the respective Copyright Law.

The use of general descriptive names, registered names, trademarks, service marks, etc. in this publication does not imply, even in the absence of a specific statement, that such names are exempt from the relevant protective laws and regulations and therefore free for general use.

While the advice and information in this book are believed to be true and accurate at the date of publication, neither the authors nor the editors nor the publisher can accept any legal responsibility for any errors or omissions that may be made. The publisher makes no warranty, express or implied, with respect to the material contained herein.

Printed on acid-free paper

Humana Press is a brand of Springer
Springer is part of Springer Science+Business Media (www.springer.com)

During the execution of this book the world has lost a leader in the field of Lysosomal Storage Disorders. Ed Wraith, one of the key contributors to the book - died suddenly in Manchester in April 2013. Ed was a pioneer in every aspect of LSDs including cellular therapy. Indeed Jaap Jan Boelens and Rob Wynn first met each other at a meeting attended and chaired by Ed to facilitate collaboration between European metabolic disease transplant centres. It is a testament to Ed and to his vision for LSD patients and their families that this collaboration has taken root and borne the fruit of hugely improved knowledge about transplant and of course much better patient outcomes. As we look to the future in this book then we remember Ed for all that he taught us and the shining example that he was of the complete physician for his patients. We dedicate this book to his memory.

Rob Wynn, Manchester. May 2013
Jaap Jan Boelens, Utrecht. May 2013

Preface

Inborn errors of metabolism (IEM) are a diverse group of diseases arising from genetic defects in lysosomal enzymes or peroxisomal function. Lysosomal enzymes are hydrolytic and are stored in cellular organelles called lysosomes. Peroxisomes are subcellular organelles involved in lipid metabolism. These diseases are characterized by devastating systemic processes affecting neurologic and cognitive function, growth and development, and cardiopulmonary status. Onset in infancy or early childhood is typically accompanied by rapid deterioration and results in early death in the most severe phenotypes.

Therefore, timely diagnosis and immediate referral to an IEM specialist are essential steps in the management of these disorders. Nowadays various treatment modalities are available for these devastating disorders. Initially only hematopoietic cell transplantation (HCT) was a treatment option in a selected group of disorders. Later (early 2000s) intravenous enzyme replacement therapy became available for some diseases, e.g., MPS-1, 2, 6, Gaucher, Fabry. Furthermore, substrate deprivation therapy is being trialed as well and major progress is made in the development of gene therapy (GT), of which the first trials are currently running. In the future iPSC and ES therapies may reach the clinic.

Treatment recommendations are based on the disorder; its phenotype including age at onset, rate of progression, and severity of clinical signs and symptoms; family values and expectations; and the risks and benefits associated with available therapies such as HCT or more recent experimental GT trials. HCT for IEM is performed using donor cells from bone marrow (BM), umbilical cord blood (CB), or growth factor-mobilized peripheral blood (PB). Donor cells are infused into the patient after myelo-suppression and immunosuppression, using chemotherapeutic agents.

To study the effect of the various treatment modalities in these rare diseases, international collaborative efforts are of utmost importance, and they began in the late 1980s and continue till today. Large multi- and single-center reports on the outcomes of HCT have been published on MPS IH (Boelens, Peters, etc.), cerebral X-ALD

(Peters, Beams, Orchard), and GLD (Escobar). This book will focus on stem cell therapies in IEM; an international perspective on progress, limitations, and future directions (e.g., gene therapy, iPS, ES) in the field is provided.

Utrecht, The Netherlands
Manchester, UK

Jaap Jan Boelens
Robert Wynn

Contents

1	Lysosomal Diseases and Therapeutic Options: An Overview.....	1
	Eveline J. Langereis and Frits A. Wijburg	
2	Alternative Treatment Options: Enzyme Replacement and Small Molecule Therapies	21
	James Edmond Wraith and Simon Jones	
3	Hematopoietic Cell Transplantation in Inborn Errors of Metabolism	37
	Jaap J. Boelens, Paul Szabolcs, and Rob Wynn	
4	Leukodystrophies and Lysosomal Storage Disorders.....	63
	Maria L. Escolar and Mieke Aldenhoven	
5	Hematopoietic Stem Cell Gene Therapy for Lysosomal Storage Disorders: Expected Benefits and Limitations.....	127
	Alessandra Biffi and Ilaria Visigalli	
6	Alternative Future Therapies for Lysosomal Storage Diseases: Embryonic Stem Cell- and Induced Pluripotent Stem Cell Therapy	139
	Arie Koen Braat, Paul J. Coffey, and Niels Geijsen	
7	Concluding Comments and Future Directions.....	159
	Robert Wynn and Jaap Jan Boelens	
	Index.....	167